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Background:Hypertrophic cardiomyopathy (HCM) patientsmay develop interatrial activation delay, indicated by
a complete separation of the right and left atrial activation on the ECG. This study aimed to determine the prev-
alence of interatrial activation delay and the relation to atrial tachycardia (AT) cycle length (CL) in HCMpatients.
Methods: 159 HCM patients were included (mean age 52 ± 14 y). In group I (n= 15, 9%) patients had atrial ar-
rhythmias and progressive ATCL. In group II (n= 22, 14%) patients had a stable ATCL. In group III (n= 122, 77%)
HCM patients without AT were included. P wave morphology and change in P wave duration (ΔP and Pmax) and
changes in ATCL (ΔATCL) were analyzed. Mean follow-up was 8.7 ± 4.7 years.
Results: In group I 33% (n = 5) had separated P waves. In group II no P wave separation was identiﬁed (OR
1.50 [1.05–2.15], p = 0.007). In group I patients were older compared to group III (62.6 ± 15.1 vs. 50.2 ±
14.0 y, p = 0.002) and had longer follow-up (13.4 ± 2.2 vs. 7.8 ± 4.6 y, p b 0.001). In group III Pmax and
ΔP were signiﬁcantly lower (105.1 ± 22.0 ms and 8.9 ± 13.2 ms, both p b 0.0001). Group I patients had
an increased LA size compared to group II (61.1 ± 11.6 vs. 53.7 ± 7.5 mm, p = 0.028) and higher E/A
and E/E prime ratios (p = 0.007; p = 0.037, respectively). In group I 93.3% of the identiﬁed mutations
were typical Dutch founder mutations of the MYBPC3 gene.
Conclusion: In HCM patients a unique combination of separated P waves and regularization of ATs is associ-
ated with larger atria, higher LA pressures and myosin binding protein mutations.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hypertrophic cardiomyopathy (HCM) is recognized to be an impor-
tant cause of morbidity and mortality in people of all ages [1]. Patients
with HCM have a higher risk of developing ventricular as well as atrial
arrhythmias [2–4]. Intra- and interatrial conduction and refractory
properties are signiﬁcantly inﬂuenced by the degeneration of the atrial
septum and the Bachmann's bundle [5–7]. Prolongation of interatrial
conduction times (reﬂecting in longer Pwaves) and LAdiameter are sig-
niﬁcant predictors for atrial ﬁbrillation and other atrial tachyarrhyth-
mias [8–11]. Our group recently observed a unique association with P
wave separation on the ECG and development of progressively slowing
regular atrial tachycardia in a patient diagnosed with hypertrophic car-
diomyopathy [12]. The primary aim of this study was to assess the clin-
ical magnitude of this phenomenon and to evaluate its possible clinicalability and freedom from bias of
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bus 2040, 3000 CA Rotterdam,
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land Ltd. This is an open access articlimpact in a larger cohort of patients with HCM. The secondary aim of
this studywas to identify prognostic factors and possible clinical predic-
tors for this novel clinical entity.
2. Methods
In this case–control study data was used from our HCM registry
from 1995 until the present, which includes patients with a con-
ﬁrmed genetic mutation. Data were collected and analyzed in accor-
dance with the hospital institutional review board policies. A total of
175 patients (67.4% male) were analyzed with a mean age of 53 ±
14 years. Diagnosis of HCM was based on echocardiographic pres-
ence of a hypertrophied, non-dilated left ventricle (LV) with a max-
imal LV wall thickness ≥15 mm and an absence of other cardiac or
systemic disease that might lead to LV hypertrophy.
2.1. P wave measurements
P wave measurements were performed in all recorded 12-lead ECG
recordings at a sweep speed of 25mm/s and10 mV/cmstandardization.
Both P wave morphology and changes in P wave duration (PWD) weree under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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signal from baseline and returning to baseline for positive waveforms,
and the ﬁrst negative deﬂection until returning to baseline for negative
waveforms. Measurements were performed manually and ECGs were
carefully analyzed using up to 12 times magniﬁcations using Adobe
Reader 8.0 (Adobe Systems Incorporated, CA, USA). PWDwasmeasured
in the limb leads and maximum PWD was considered the actual atrial
conduction time. If the P wave had respectively two upward or down-
ward departures from baseline it was deﬁned as a separated Pwave, in-
dicating separated activation of the atria. In all patients both Pmax and
ΔP were analyzed, indicating maximum P wave and change of PWD
during follow-up. The ΔP was deﬁned as the difference between the
maximum and minimum PWD and was only calculated for patients
who underwent at least two years of follow-up. The Pmax was used as
a marker of prolonged atrial conduction time, whereas theΔP indicated
variable conduction properties of the atria.
2.2. Atrial arrhythmias
The incidence of atrial arrhythmias was evaluated for all HCM pa-
tients. Data from ECG recordings taken either during routine examina-
tion at the out-patient clinic or hospital stay were analyzed.
Furthermore, 24 h Holter registrations were examined to determine
any incidence of atrial arrhythmias. In total, 20.6% (n = 36) of the pa-
tients suffered only from atrial ﬁbrillation (AF), 2.3% (n = 4) had only
atrial ﬂutter, 0.6% (n = 1) had only AT, 4.6% (n = 8) had both AF and
AFl, 0.6% (n = 1) had AF and AT, and in 1.7% (n = 3) AF, AT and AFl
were all documented. From all 12-lead arrhythmia recordings
the cycle length of the atrial arrhythmia (ATCL) was measured
in precordial leads using the same techniques as for P wave mea-
surements. The ΔATCL was calculated and deﬁned as the differ-
ence between the longest and the shortest recorded ATCL during
follow-up. It was only calculated if more than two 12-lead ECG
captured the atrial arrhythmia with at least one-year time interval
(n = 37).
2.3. Study groups
From the baseline population, a total of 16 patients were exclud-
ed due to insufﬁcient follow-up (n = 13) or permanent AF (n = 3).
From the remaining HCM population two groups of patients were se-
lected and analyzed in this study. All included patients who suffered
from atrial arrhythmias (n = 37). In the ﬁrst study group (group I, n =
15) patients had a progressive ATCL during follow-up. In the second
group (group II, n = 22) patients had a stable ATCL (deﬁned as a
ΔATCL b 10 ms). From all patients the presence of a visible separated
P wave on the surface ECG was evaluated together with other sec-
ondary endpoint parameters and compared between the two study
groups. Additional comparison of group I patients with the general
HCM population (group III, n = 122) without atrial arrhythmias
and P wave separation whomet the criteria for P wave measurement
was also performed.
Patients underwent a median follow-up of 9.0 years (IQR [4.0–
13.0 y]) commencing when the ﬁrst 12-lead ECG was recorded during
the initial clinical presentation at our institute up until the most recent
ECG recording.
2.4. Echocardiography
In all patients complete transthoracic 2-dimensional echocardiogra-
phy was performed. Echocardiographic studies were performed with a
Sonos 7500 ultra-sound system with a S3 transducer or an iE33
system with a S5-1 transducer (Philips Medical Systems, Best, The
Netherlands). From the second harmonic M-mode recordings the fol-
lowing echocardiographic parameters were taken: LA size, intraventric-
ular septal thickness, LV end-diastolic volume, degree of mitralregurgitation, E/A ratio, E/E prime ratio and fractional shortening
(FS). The FS was calculated using the following formula: (LV end-
diastolic diameter − LV end-systolic diameter) / LV end-diastolic
diameter × 100%. Echocardiography showed that 29.7% of patients
(n = 11) had an obstructive HCM and 70.3% a non-obstructive
HCM (n = 26). Obstructive HCM was deﬁned as a resting peak
LVOT gradient N30 mm Hg. All measurements were calculated ac-
cording to ACC/AHA guidelines [13].2.5. Genetics
All included patients underwent genetic mutation testing prior to
this study. These tests revealedmutations in themyosin binding protein
C (89.2%), myosin heavy chain beta (5.4%), troponin T type 2 (2.7%) and
tropomyosin 1 (1.1%). In the reference HCM population the following
genetic mutations were found: myosin binding protein C (82.8%), myo-
sin heavy chain beta (13.1%), troponin T type 2 (0.8%), troponin I type 3
(0.8%), tropomyosin 1 (0.8%) and myosin regulatory light chain 2
(1.6%). In this study correlations were made between any of these
known genetic mutations.2.6. Statistics
The Kolmogorov–Smirnov test was used to assess the normality of
distribution. Descriptive statistics was presented asmean± SD for con-
tinuous variables if normally distributed. In the case of non-normal dis-
tribution of data, median and interquartile range (IQR) were reported.
Continuous data was compared with the Student's t test or Mann–
Whitney U test, where appropriate. Categorical data was presented as
percentages and compared with the Chi-square test or Fisher's exact
test when appropriate. Univariate analyses were performed for all vari-
ables and odds ratios (OR) and 95% conﬁdence intervals (95% CI) were
determined. Statistical analysis was performed with PASW version 18
(IBM Corp., Somers, NY). Statistical signiﬁcance is deﬁned as p b 0.05
(two-tailed).3. Results
3.1. Study population
The demographics and clinical presentation of all patients are shown
in Table 1. Group I and group II patients were homogenouswith respect
to gender and clinical symptoms. Furthermore, both groups had equal
distribution of atrial tachyarrhythmias (AF, AT and AFl). There were
nodifferences in the amount of implanteddevices and theneed for elec-
trical cardioversion therapy. Furthermore, in one group I patient 83 ep-
isodes of anti-tachycardia pacing (ATP) and one shock was delivered.
One patient from group II received 5 ATP episodes and 5 ICD shocks.
In group III 21.4% of patients with an ICD received appropriate therapy.
The use of diuretics, angiotensin-converting-enzyme inhibitors, angio-
tensin receptor blockers, beta-blockers, calcium channel blockers, aspi-
rin, warfarin and statin was comparable for both group I and group II.
Furthermore, the use of amiodarone was not different for both groups
(46.7% vs. 27.3%, p= 0.194). Patients in group I had signiﬁcantly longer
follow-up when compared to group II (13.4± 2.2 vs. 10.9± 3.9 y, p=
0.033).
The reference HCM population, group III, was also comparable in
terms of gender and clinical presentations. The signiﬁcant differ-
ences found in this study were related to the absence of tachyar-
rhythmias in this group compared to group I (palpitations, AF, AT,
AFl, cardioversion, amiodarone), which was the basis of the group
selection. However, the study population was signiﬁcantly older
than the reference population and had a longer follow-up (62.6 ±
15.1 vs. 50.2±14.0 y, p= 0.002; 13.4±2.2 vs. 7.8± 4.6 y, p b 0.0001).
Table 1
Demographics of HCM population. Percentages, odds ratios and conﬁdence intervals of 95% obtained by univariate analyses.
Variable Group I Group II OR 95% CI p-Value Group III OR 95% CI p-Value
Number of patients (n) 15 22 122
Age (y) 62.6 ± 15.1 56.6 ± 11.5 0.201 50.2 ± 14.0 0.002
P wave separation (%) 33.3% (n = 5) 0.0% (n = 0) 1.50 [1.05–2.15] 0.007 3.3% (n = 4) 14.75 [3.41–63.81] 0.001
Gender (male %) 60.0% (n = 9) 57.9% (n = 11) 1.09 [0.28–4.32] 0.590 71.3% (n = 87) 0.60 [0.20–1.82] 0.267
Angina (%) 20.0% (n = 3) 10.5% (n = 2) 2.13 [0.31–14.73] 0.384 20.0% (n = 25) 0.97 [0.25–3.70] 0.634
Dyspnea (%) 46.7% (n = 7) 68.4% (n = 13) 0.40 [0.10–1.64] 0.177 30.3% (n = 37) 2.01 [0.68–5.95] 0.162
Syncope (%) 20.0% (n = 3) 5.3% (n = 1) 4.50 [0.42–48.53] 0.216 9.0% (n = 11) 2.52 [0.62–10.32] 0.183
Palpitations (%) 53.3% (n = 8) 42.1% (n = 8) 1.57 [0.40–6.14] 0.380 23.8% (n = 29) 3.67 [1.22–10.97] 0.021
Family history (%) 46.7% (n = 7) 68.4% (n = 13) 0.40 [0.10–1.64] 0.177 65.6% (n = 80) 0.46 [0.16–1.35] 0.126
HOCM (%) 33.3% (n = 5) 27.3% (n = 6) 1.33 [0.32–5.55] 0.484 24.6% (n = 30) 1.53 [0.49–4.84] 0.326
AF (%) 100% (n = 15) 95.5% (n = 21) 0.96 [0.87–1.05] 0.595 0.0% (n = 0) NA b0.0001
AT (%) 20.0% (n = 3) 4.5% (n = 1) 5.25 [0.49–56.26] 0.172 0.0% (n = 0) NA 0.001
AFl (%) 26.7% (n = 4) 27.3% (n = 6) 0.97 [0.21–4.26] 0.635 0.0% (n = 0) NA b0.0001
NSVT (%) 60.0% (n = 9) 50.0% (n = 11) 1.50 [0.40–5.67] 0.397 36.9% (n = 45) 2.57 [0.86–7.68] 0.075
PM (%) 20.0% (n = 3) 9.1% (n = 2) 2.50 [0.36–17.17] 0.317 0.8% (n = 1) 30.25 [2.92–313.91] 0.004
ICD (%) 20.0% (n = 3) 18.2% (n = 4) 1.13 [0.21–5.95] 0.606 11.5% (n = 14) 1.93 [0.48–7.68] 0.278
Cardioversion (%) 80.0% (n = 12) 72.7% (n = 16) 1.50 [0.31–7.25] 0.459 0.0% (n = 0) NA b0.0001
ACEI (%) 33.3% (n = 5) 31.8% (n = 7) 1.07 [0.26–4.34] 0.599 18.9% (n = 23) 2.15 [0.67–6.90] 0.164
Amiodarone (%) 46.7% (n = 7) 27.3% (n = 6) 2.33 [0.59–9.29] 0.194 1.6% (n = 2) 52.50 [9.34–295.18] b0.0001
ARB (%) 20.0% (n = 3) 13.6% (n = 3) 1.58 [0.27–9.17] 0.468 5.7% (n = 7) 4.11 [0.94–18.00] 0.080
Aspirin (%) 13.3% (n = 2) 4.5% (n = 1) 3.23 [0.27–39.29] 0.356 10.7% (n = 13) 1.29 [0.26–6.36] 0.511
BB (%) 53.3% (n = 8) 59.1% (n = 13) 0.79 [0.21–2.97] 0.495 42.6% (n = 52) 1.54 [0.53–4.51] 0.302
CCB (%) 6.7% (n = 1) 13.6% (n = 3) 0.45 [0.04–4.82] 0.461 10.7% (n = 13) 0.60 [0.07–4.93] 0.529
Diuretics (%) 66.7% (n = 10) 40.9% (n = 9) 2.89 [0.74–11.36] 0.114 11.5% (n = 14) 15.43 [4.60–51.70] b0.0001
Statin (%) 33.3% (n = 5) 22.7% (n = 5) 1.70 [0.39–7.36] 0.365 6.6% (n = 8) 7.13 [1.96–25.91] 0.006
Warfarin (%) 86.7% (n = 13) 72.7% (n = 16) 2.44 [0.42–14.16] 0.277 4.1% (n = 5) 152.10 [26.78–864.02] b0.0001
ACEI: angiotensin-converting-enzyme inhibitor, AF: atrial ﬁbrillation, AFl: atrial ﬂutter, ARB: angiotensin receptor blocker, AT: atrial tachycardia, BB: beta blocker, CCB: calcium channel
blocker, HOCM: hypertrophic obstructive cardiomyopathy, ICD: implantable cardioverter-deﬁbrillator, NSVT: non-sustained ventricular tachycardia, PM: pacemaker.
Bold values indicate signiﬁcance at P-value b 0.05.
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Of the 15 group I patients with a progressive ATCL over time,
33.3% (n = 5) had a complete P wave separation on the surface elec-
trogram (Figs. 1 and 2). In none of the group II patients a separated P
wave could be identiﬁed (OR 1.50 [1.05–2.15], p = 0.007). The me-
dian ΔATCL for group I patients was 61.7 ms (IQR [20–60 ms]). The
Pmax was not statistically different for group I or group II patients,Total HCM registry 
(n=175) 
Included in study 
(n=159) 
Group III  
(n=122) 
P wave separation 
(3.3%, n=4) 
Group II  
(n=22) 
P wave separation 
(0.0%, n=0) 
Group I  
(n=15) 
P wave separation 
(33.3%, n=5) 
Excluded patients 
(n=16) 
Permanent AF  
(n=3) 
Insufficient follow up 
(n=13) 
Fig. 1. Flow chart of the patients included in each study group— For all groups the amount
of patients with P wave separation is reported.although it tended to be higher in group I (142.3 ± 30.9 vs. 126.4 ±
18.1 ms, p = 0.062). The ΔP wave was also comparable (36.4 ± 25.3
vs. 22.6 ± 16.3 ms, p = 0.066).
In the reference HCM population without atrial arrhythmias, a com-
plete separated P wave was visible in 4 patients. However, the preva-
lence was signiﬁcantly higher in group I patients (33.3% vs. 3.3%, p =
0.001). Furthermore, the Pmax and the ΔP were signiﬁcantly lower for
group III patients (p b 0.0001, Table 2).3.3. Echocardiography
Two-dimensional echocardiography studies showed LA size to be
signiﬁcantly larger in group I patients compared to group II (61.1 ±
11.6 vs. 53.7 ± 7.5 mm, p = 0.028). The same results were found
when compared to group III patients (45.4 ± 7.9 mm, p b 0.0001).
Both the E/A and E/E prime ratios were higher for patients in group I
than in group II (3.0 ± 1.5 vs. 1.8 ± 0.9, p = 0.007; 19.3 ± 9.1 vs.
12.2 ± 6.9, p = 0.037). FS, degree of mitral regurgitation, IV septum
thickness, LV end-diastolic volume, E velocity, A velocity and E deceler-
ation timewere all comparable for both group I and group II patients. In
patients with a separated P wave, echocardiography showed that the A
wave of both atria consisted of separate curves on theM-mode imaging
of the mitral ﬂow (Fig. 3). The A1 wave represented the contraction of
the RA, whereas A2 indicated the contraction of the LA.
When group I patientswere compared to group III patients, echocar-
diography showed that group I patients had signiﬁcantly less FS, more
mitral regurgitation and higher E/A and E/E prime ratios (Table 2).3.4. Genetic mutations
With respect to geneticmutations no signiﬁcant differences could be
found when patients from all groups were compared (Table 3). The
most frequent mutations were typical Dutch founder mutations of the
MYBPC3 gene, which was present in 93.3% of group I patients, 86.4%
in group II and 82.8% in group III (p = ns).
2003 2005 2007 2009 2009 2013
I
II
III
aVR
aVL
aVF
V1
V2
V3
V4
V5
V6
200 ms
0.5 mV
Fig. 2. Twelve-lead surface electrocardiograms from 2003 until 2013 from a group I patient— The progression of P-wave separation is clearly visible in sinus rhythm. Furthermore, the P-
waves from lead I are displayed enlarged for each year. Over time, the surface electrocardiogram shows changed in repolarization as well.
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Table 2
Electrocardiological and echocardiographic parameters (univariate analysis).
Variable Group I Group II p-Value Group III p-Value
Follow-up (y) 13.4 ± 2.2 10.9 ± 3.9 0.033 7.8 ± 4.6 b0.0001
Pmax (ms) 142.3 ± 30.9 126.4 ± 18.1 0.062 105.1 ± 22.0 b0.0001
ΔP wave (ms) 36.4 ± 25.3 22.6 ± 16.3 0.066 8.9 ± 13.2 b0.0001
ΔATCL (ms) 61.7 [IQR 20–60] NA NA
LA volume (mL) 61.1 ± 11.6 53.7 ± 7.5 0.028 45.4 ± 7.9 b0.0001
FS (%) 33.1 ± 7.8 31.5 ± 11.5 0.674 40.4 ± 8.9 0.004
MR grade 1.1 ± 1.1 0.9 ± 1.2 0.498 0.4 ± 0.7 0.001
IVST (mm) 17.0 ± 5.0 16.3 ± 4.7 0.687 19.7 ± 5.7 0.086
LVEDV (mL) 48.9 ± 6.8 50.7 ± 7.8 0.480 45.1 ± 6.1 0.030
E velocity (m/s) 0.8 ± 0.3 0.7 ± 0.3 0.356 0.6 ± 0.2 0.002
A velocity (m/s) 0.3 ± 0.2 0.5 ± 0.2 0.079 0.6 ± 0.2 b0.0001
E/A 3.0 ± 1.5 1.8 ± 0.9 0.007 1.2 ± 0.5 b0.0001
E/E′ 19.3 ± 9.1 12.2 ± 6.9 0.037 13.1 ± 6.0 0.001
EDT 174.7 ± 68.4 183.3 ± 69.6 0.721 201.4 ± 73.3 0.187
MR: mitral regurgitation, ATCL: atrial tachycardia cycle length, LA: left atrium, FS: fractional shortening, IVST: intraventricular septal thickness, LVEDV: left ventricular end-diastolic vol-
ume, EDT: E wave deceleration time.
Bold values indicate signiﬁcance at P-value b 0.05.
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The major ﬁnding of this study is that a subgroup of HCM patients
with a unique combination of signs namely separated P wave, regulari-
zation and slowing ATs can be identiﬁed. Our data strongly suggest that
this observation does not represent isolated cases, but is consistentwith
the presence of a unique clinical entity within the HCM group.
Therefore, we propose to call this as “double hump syndrome” naming
after the very typical appearance on the surface electrocardiogram. It
seems that extreme interatrial conduction delay is the underlyingHcm
2006
2010 
E 
A1 
A2 
E 
A1 A2 
E 
A1 
A2 A2 
A1 
E 
Fig. 3. Echocardiographic images from 2006 and 2010 displaying mitral inﬂow— E wave:
diastolic mitral inﬂow. A1 wave: inﬂow during right atrial contraction. A2 wave: inﬂow
during left atrial contraction.electrophysiological mechanism for the symptoms. This clinical presen-
tation is associated with larger atria and higher LA pressures.
4.1. Genetical background
Most MYBPC3 mutations are truncating mutations and are in con-
trastwith other sarcomeric genes in HCM,which are generallymissense
mutations [14]. It is thought that these truncated mutations cause a re-
duction in MYBPC3 protein due to the lack of expression from the mu-
tant allele by the cellular surveillance mechanism of nonsense-
mediated decay [15]. The effect of MYBPC3 protein on the atrium is
not completely discovered. During experimental setups it has been
demonstrated that the deletion of MYBPC3 causes an increase of short-
ening velocity, force output and force redevelopment on a ventricular
level. [16–18]. The effect of MYPBC3 deletion on the left atrium in
MYPBC3 knockout mice led to a prolonged sarcomere shortening and
Ca2+ transient [19]. The MYPBC3 deletion on the left atrial level caused
a marked increase in sensitivity to external Ca2+ and low micromolar
Ca2+. The consequencewas a defect in diastolic relaxation and a smaller
dynamic range of cell shortening, as a result of the increased myoﬁla-
ment Ca2+ sensitivity [19,20]. Obviously the link between the genetical
background and the development of this syndrome should be further
investigated. Thiswill lead us to further understand the arrhythmia gen-
esis in patients with HCM.
4.2. The role of amiodarone: unmasking the presence of susceptibility for
interatrial conduction delay
Interestingly enough, in this study the use of amiodarone has been
associated with the presence of double hump syndrome. This raises
the important question of whether the relationship between these enti-
ties is simply coincidental or that possibly a causative relationship plays
a role. To the best of our knowledge amiodarone has no signiﬁcant
lengthening effect on PWD and actually on the contrary it decreases
PWD according to most available literature [21,22]. The effect on the
electrophysiological properties of interatrial conduction delay is sparse
and further investigation is necessary to understand it clearly. It is fairly
remarkable that in our study amiodarone use was associated with in-
creased PWD and P wave separation. As has been demonstrated before
in different experimental settings, chronic amiodarone use prolongs the
atrial action potential duration, which eventually leads to an increased
total atrial activation time and increased PWD [23–25]. This raises the
possibility that indeed the effect could be disease speciﬁc. Based on
the above-mentioned ﬁndings, amiodarone may have unmasking ef-
fects. In this scenario the electrophysiological effects of amiodarone
for the intra-atrial conduction delay would be very useful in patients
prone to develop double hump syndrome, by using it to unmask this
Table 3
Genetic mutations. Percentages, odds ratios and conﬁdence intervals of 95% obtained by univariate analyses.
Variable Group I Group II OR 95% CI p-Value Group III OR 95% CI p-Value
MYPC3 (%) 93.3% (n = 14) 86.4% (n = 19) 2.21 [0.21–23.56] 0.461 82.8% (n = 101) 2.91 [0.36–23.56] 0.263
MYH7 (%) 6.7% (n = 1) 4.5% (n = 1) 1.50 [0.09–26.01] 0.653 13.1% (n = 16) 0.47 [0.06–3.85] 0.415
TNNT2 (%) 0.0% (n = 1) 4.5% (n = 1) 0.96 [0.87–1.05] 0.595 0.8% (n = 1) NA 0.891
TNNI3 (%) 0.0% (n = 0) 0.0% (n = 0) NA NA 0.8% (n = 1) NA 0.891
TPM1 (%) 0.0% (n = 0) 4.5% (n = 1) 0.96 [0.87–1.05] 0.595 0.8% (n = 1) NA 0.891
MYL2 (%) 0.0% (n = 0) 0.0% (n = 0) NA NA 1.6% (n = 2) NA 0.792
MYPC3: myosin binding protein C, MYH7: myosin heavy chain 7, TNNT2: troponin T type 2, TNNI3: troponin I type 3, TPM1: tropomyosin 1, MYL2: myosin regulatory light chain 2.
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possibility is that these patients all developed atrial tachyarrhythmias.
Atrial tachyarrhythmias can have a very deleterious effect on the hemo-
dynamics of HCM patients. Therefore, it is not a surprise that eventually
most of these patients were treated with the most effective class III an-
tiarrhythmics [26].
4.3. Time as a factor: slow development of double hump syndrome
In this study longer follow-up and older age were clearly associated
with the development of double hump syndrome. This means that the
development of the syndrome is fairly slow and time-dependent. This
is not surprising when looking at the possible underlying mechanisms
behind it. Our ECG and echocardiographic Doppler data all support the
evidence that the delay in impulse propagation occurs on the level of
the interatrial septum, rather than in the atria itself. When the delay is
fully developed, almost complete atrial dissociation could be observed.
Given the fact that this is associatedwith the appearance of atrial tachy-
arrhythmias it is highly suggestive that a certain form of degeneration
or scaring plays a role. Furthermore, the long course of development in-
dicates that the presence of this syndrome may have no signiﬁcant ef-
fect on mortality. This is slightly overshadowed by the fact that 20% of
patients with double hump syndrome had an ICD implanted. The ICDs
gave in total 83 appropriate ATP episodes and one delivered shock in
one patient. Multicentre studies, even in registry form would be able
to answer this question. Another consequence of this slowdevelopment
is that the HCM patients should be carefully screened for this through-
out their life, especially, when they develop atrial tachyarrhythmias.
4.4. Limitations of the study
The major limitation of this study that all ﬁndings included is based
on non-invasive tests. The accurate electrophysiological mechanisms
should be later determined by performing a series of electrophysiology
studies. The true prevalence and incidence of this unique subgroup of
HCM patients should be studied in a multicentre study. In a later stage
the genetical background and possible relations with the clinical and
long-term outcome should be investigated in a more meticulous
manner.
Furthermore, additional magnetic resonance imaging performed in
all patients could provide valuable information regarding interatrial
septum thickness. Changes in the interatrial septumcould have an inﬂu-
ence on the PWD and P wave separation and might explain the differ-
ences among the three groups of patients. Therefore, further studies
are needed to reveal this issue.
5. Conclusion
A subgroup of HCM patients has a unique combination of symptoms
of separated P wave, regularization and slowing of ATs (the “double
hump syndrome”). Clinically it is associated with larger atria, higher
LA pressures and longer follow-up. The presence of “double hump syn-
drome” is mostly associated with MYBPC3 myosin binding protein mu-
tations. Extreme interatrial conduction delay might be the underlying
electrophysiological mechanisms of this clinical presentation.Funding
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